MedTrace Logo

Combination of Conditioned Medium and Umbilical Cord-Mesenchymal Stem Cells Therapy for Acute Stroke Infarct

NCT05008588 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-02-25

No results posted yet for this study

Summary

The purpose of this study was to determine the effectiveness of a combination of intranasal conditioned medium (CM) with intraparenchymal umbilical cord mesenchymal stem cells (UC-MSCs) transplantation in acute stroke patients to induce neurogenesis.

Conditions

Interventions

BIOLOGICAL

Umbilical Cord Mesenchymal Stem Cells

Intra-parenchymal transplantation of 20x10\^6 UC-MSCs

PROCEDURE

Neurologic and Neutrophic Drugs

Such as clopidogrel, piracetam, citicoline

BIOLOGICAL

Conditioned Medium

Intranasal of 3 cc of conditioned medium each, for 3 days in a row

Sponsors & Collaborators

  • PT. Prodia Stem Cell Indonesia

    lead INDUSTRY

Principal Investigators

  • Rima Haifa · Prodia StemCell Indonesia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
25 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-30
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05008588 on ClinicalTrials.gov